Asaf Shiloni

Asaf Shiloni is the Chief Executive Officer of Kadimastem Ltd., a clinical-stage biotechnology company focused on cell therapy. He has over 20 years of executive experience in the biotech industry, particularly in the field of cell therapy.

Career Highlights

• PeproTech Inc.: Before joining Kadimastem, Shiloni spent 13 years at PeproTech, where he served as Vice President of Sales and Business Development. He played a significant role in establishing collaborations with major U.S. stem cell companies and led mergers and acquisitions efforts.13
• CytoLab: Shiloni co-founded CytoLab in 2007, a biotech company specializing in proteins, antibodies, and assays. He successfully sold the company after seven years.14
• ABN Global: Earlier in his career, he was the CEO of ABN Global, a technology startup, where he was instrumental in raising capital and driving growth.1

Education

Shiloni holds a Bachelor's degree in Computer Information Systems and Business from The College of Management and an MBA from Tel Aviv University.12

Industry Impact

His extensive knowledge of the biotechnology market and strong connections with the global investment community have contributed to his reputation as a leader in the field. Under his leadership, Kadimastem is advancing innovative therapies for neurodegenerative diseases such as ALS.34